Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.
3.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
5.

Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.

Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA.

Cancer Treat Rev. 2012 Jun;38(4):318-28. doi: 10.1016/j.ctrv.2011.06.009. Review.

PMID:
21775065
6.

Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

Price DT, Ridker PM.

Ann Intern Med. 1997 Nov 15;127(10):895-903. Review.

PMID:
9382368
7.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
8.
9.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
10.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
11.

Chemoprevention in postmenopausal women.

Rastogi P.

Menopause. 2008 Jul-Aug;15(4 Suppl):810-5. doi: 10.1097/gme.0b013e318178863e. Review.

PMID:
18596603
13.

National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S. Review.

14.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

15.

[From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A].

Reitsma PH, van de Stolpe A.

Ned Tijdschr Geneeskd. 2001 Sep 22;145(38):1843-5. Review. Dutch.

PMID:
11593787
16.

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR.

BMJ. 1996 Nov 2;313(7065):1127-30. Review.

17.

The effect of SERMs on the endometrium.

Goldstein SR.

Ann N Y Acad Sci. 2001 Dec;949:237-42. Review.

PMID:
11795358
18.

Reducing the risk of breast cancer with tamoxifen in women at increased risk.

Vogel VG.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):87S-92S. Review.

PMID:
11560980
19.

Genetic risk factors of venous thrombosis.

Franco RF, Reitsma PH.

Hum Genet. 2001 Oct;109(4):369-84. Review.

PMID:
11702218
20.

Tamoxifen in ductal carcinoma in situ.

Daly MB.

Semin Oncol. 2006 Dec;33(6):647-9. Review.

PMID:
17145343
Items per page

Supplemental Content

Support Center